Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.81 |
| ▸ | ESR1 | P03372 | 3/20 | 0.81 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.67 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7462068 | 0.86 | ESR1 (0.60) | ESR2ESR1ERAP1HSD17B3CA12 | |
| SCHEMBL5088527 | 0.86 | ESR1 (0.88) | ESR2ESR1ERAP1HSD17B3CA12 | |
| SCHEMBL7125098 | 0.83 | ESR1 (0.55) | ESR2ESR1ERAP1CA12CA9 | |
| SCHEMBL31675804 | 0.83 | ERAP1 (0.62) | ESR2ESR1ERAP1HSD17B3CA12 | |
| SCHEMBL7164709 | 0.83 | ERAP1 (0.62) | ESR2ESR1ERAP1HSD17B3CA12 | |
| SCHEMBL7121802 | 0.82 | ALDH1A1 (0.64) | ESR2ESR1NPC1KDM4EGAA | |
| SCHEMBL5109410 | 0.82 | ESR1 (0.81) | ESR2ESR1ERAP1HSD17B3NPC1 | |
| SCHEMBL5107909 | 0.82 | ESR1 (0.67) | ESR2ESR1ERAP1HSD17B3NPC1 | |
| SCHEMBL7120589 | 0.81 | ESR2 (0.53) | ESR2ESR1ERAP1CA12CA9 | |
| SCHEMBL13241261 | 0.81 | ESR1 (1.00) | ESR2ESR1ERAP1HSD17B3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | ESR2 3/4885ESR1 1/4885ERAP1 1675/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | ESR2 3/4885ESR1 1/4885ERAP1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.